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Abstract: B-type natriuretic peptide (BNP) is a member of the natriuretic peptide family, 
a group of widely distributed, but evolutionarily conserved, polypeptide mediators that exert 
myriad cardiovascular effects. BNP is a potent vasodilator with mitogenic, hypertrophic and 
pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases. Circulating 
levels of BNP correlate with mean pulmonary arterial pressure (mPAP) and pulmonary vascular 
resistance (PVR) in patients with pulmonary arterial hypertension (PAH). Elevated plasma 
BNP levels are associated with increased mortality in patients with PAH and a fall in BNP 
levels after therapy is associated with improved survival. These findings have important clinical 
implications in that a noninvasive blood test may be used to identify PAH patients at high-risk 
of decompensation and to guide pulmonary vasodilator therapy. BNP also has several biologic 
effects that could be beneficial to patients with PAH.  However, lack of a convenient method for 
achieving sustained increases in circulating BNP levels has impeded the development of BNP 
as a therapy for treating pulmonary hypertension. New technologies that allow transdermal or 
oral administration of the natriuretic peptides have the potential to greatly accelerate research 
into therapeutic use of BNP for cor pulmonale and pulmonary vascular diseases. This review 
will examine the basic science and clinical research that has led to our understanding of the role 
of BNP in cardiovascular physiology, its use as a biomarker of right ventricular function and its 
therapeutic potential for managing patients with pulmonary vascular disease.
Keywords: brain natriuretic peptide, pulmonary artery hypertension, biomarker, therapeutic 
agent
Introduction
Pulmonary arterial hypertension (PAH) is a progressive vasculopathy characterized 
by extensive remodeling of the pulmonary circulation that results in narrowing of 
the arterial lumen and impaired flow-mediated vasodilation. The marked increase in 
pulmonary vascular resistance limits the rate at which the right ventricle can pump 
blood through the lungs, causing shortness of breath and reduced functional capacity. 
The disease can occur at any age, but frequently affects young adults in the third or 
fourth decade of life who are otherwise healthy. Until recently, there were no specific 
therapies available to treat this disease and most patients progressed to right ventricular 
failure and death within 2 to 5 years of diagnosis.1 In 1995, intravenous epoprostenol 
became the first drug approved for the treatment of PAH in the United States. Since that 
time 6 more medications have been approved and several more await consideration by 
the FDA. These medications have improved survival and exercise capacity, but none 
have been able to achieve a cure and the majority of patients continue to progress to Drug Design, Development and Therapy 2009:3 270
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right ventricular failure, albeit at a slower pace. The lack of 
a cure and the severity with which PAH strikes has generated 
considerable interest in furthering the understanding of the 
pathogenesis of this disease and the development of new 
diagnostic and therapeutic modalities to manage it.
Brain natriuretic peptide (BNP) is one of several members 
of the natriuretic peptide family that are widely distributed, 
but evolutionarily conserved throughout the animal kingdom. 
The natriuretic peptides play important roles in cardiovascular 
homeostasis including regulation of vascular tone, blood 
volume, endothelial permeability, and cardiac hypertrophy. 
Cardiac BNP expression is markedly upregulated in response 
to ventricular hypertrophy or overload and circulating BNP 
levels can increase by 1 to 2 orders of magnitude. There is 
increasing evidence that BNP may be a useful marker for right 
ventricular dysfunction and predict outcome in patients with 
PAH. As such, plasma BNP may help guide clinical decision 
making in patients with newly diagnosed PAH and help gauge 
response to treatment. BNP is also a pulmonary vasodilator 
and anti-hypertrophic agent and thus, may have therapeutic 
potential to inhibit pulmonary vascular remodeling and 
maladaptive increases in right ventricular mass.
This paper examines the role of BNP in assessing the 
severity of pulmonary vascular disease and its potential as 
a therapeutic agent for the treatment of PAH. The synthesis, 
secretion and biologic properties of BNP, relevant to its role 
in mediating pulmonary vascular tone, is discussed first 
followed by a review of its inhibitory effects on pulmonary 
vascular remodeling, cardiac hypertrophy and endothelial cell 
apoptosis. Finally, potential therapeutic applications for the 
treatment of PAH and right heart failure are presented.
Pulmonary arterial hypertension
Pulmonary hypertension (PH) refers to a variety of conditions 
in which pulmonary arterial pressure (PAP) is elevated above 
normal. Mean pulmonary arterial pressure (mPAP) in a healthy 
adult at rest averages about 14 to 17 mmHg. Pulmonary 
hypertension is defined as a resting mPAP  25 mmHg or a 
mPAP  30 mmHg during exercise and a pulmonary capillary 
wedge pressure (PCWP)  15 mmHg. Providing that cardiac 
output is not elevated, this results in a pulmonary vascular 
resistance (PVR)  3 Wood units. Most patients with PAH 
have a mPAP that is considerably higher, however. In fact, 
the mean mPAP of over 600 PAH patients in the French 
pulmonary hypertension registry was 55 ± 15 mmHg, 
more than double the cut off level of 25 mmHg.2 The most 
common causes of elevated PAP are chronic lung and 
left sided heart disease. Elevated PAP in these conditions 
occurs as the result of hypoxia, loss of the pulmonary 
vascular bed or elevated pulmonary venous pressure due 
to impaired left sided heart function. Rarely, PH occurs as 
the result of abnormal constriction and remodeling of the 
pulmonary arteries in the absence of any other underlying 
cardiopulmonary disease. This type of PH represents a 
true pulmonary artery vasculopathy, described by Dresdale 
et al in 1951 as primary pulmonary hypertension.2 Since then, 
the term secondary PH has been used to describe PH associ-
ated with heart and lung disease or other identifiable causes 
of increased pulmonary vascular resistance. Major advances 
in our understanding of pulmonary vascular disease led to 
new terminology proposed during the 4th World Symposium 
on PH held in 2008 at Dana Point, California that organizes 
pulmonary hypertension into 5 groups to reflect the major 
underlying etiologies and sites of injury (Table 1).3
PAH is a disease that is characterized by hypertrophy 
and proliferation of pulmonary vascular smooth muscle 
and subsequent thickening of the medial wall of mid 
sized pulmonary arteries and the muscularization of more 
peripheral, normally non-muscularized vessels.4 Marked 
proliferation of endothelial cells in distal pulmonary arteries 
is also evident and in some areas causes near obliteration of 
the vascular lumen with evidence of recanulized channels 
(plexiform lesions). These changes in both the smooth 
muscle and endothelial layers substantially reduce the cross 
sectional area of the pulmonary vascular tree.5 At the same 
time, pulmonary vascular tone may be increased and the 
ability of the pulmonary circulation to dilate or recruit 
underutilized vessels in response to increased flow is 
reduced.6 As remodeling of the pulmonary vascular bed 
progresses, PVR rises, increasing right ventricular afterload 
and leading to decreased functional capacity and eventually 
right ventricular failure.7
The diagnosis and treatment of PAH is hampered by 
difficulty in obtaining accurate measurements of PAP. Unlike 
the systemic circulation where intravascular pressure is easily 
measured by syphgmometry, there is no accurate, readily 
available noninvasive test for measuring PAP. Right heart 
catheterization (RHC) provides the direct measurement of 
PAP and is vital in the appropriate diagnosis and evaluation 
of unexplained PH, but it is invasive and expensive and 
not amenable to repeated measurements that are necessary 
to monitor disease progression. As a result, the clinician 
must rely on a combination of indirect assessments of PAP 
and cardiac output such as transthoracic echocardiography, 
6-minute walking distance, and WHO functional class. 
A simple noninvasive, but objective measure of right Drug Design, Development and Therapy 2009:3 271
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ventricular afterload would contribute significantly to the 
management of PAH patients. Biomarkers that correlate 
with PAP and/or right sided filling pressures would allow the 
practitioner insight into how a patient’s disease is progressing 
and allow the physician to evaluate the effect of pulmonary 
vasodilator therapy. Plasma BNP levels rise in response to 
right as well as left atrial or ventricular overload and may 
be an important tool for assessing right ventricular perfor-
mance in PAH.
The treatment of PAH has grown considerably in the 
last decade. Presently, 7 different medications belonging 
to 3 distinct pharmaceutical classes are available for the 
management of PAH. However, in the great majority of 
patients, none of these treatments are capable of restoring 
normal pulmonary hemodynamics and exercise capacity and 
have limited ability to improve right heart function. Further-
more, all 3 classes focus primarily on vasodilation or remod-
eling of the pulmonary circulation. Additional therapies are 
needed that aid the right ventricle in maintaining adequate 
systolic function and inhibit maladaptive hypertrophic 
changes in response to persistent elevation in afterload.
Brain natriuretic peptide
BNP release
Human BNP is a 32-amino acid polypeptide secreted 
predominantly by the cardiac atria and ventricles. BNP 
is synthesized as a preprohormone of 134 residues 
that is cleaved to yield a 108-amino-acid prohormone 
(proBNP1 – 108). The prohormone is subsequently cleaved 
by an unknown protease to an inactive 76-residue amino-
terminal (NT) fragment known as NT-BNP and the 32 amino-
acid, carboxyl-terminal 32 fragment that is the biologically 
active peptide.8–12 The size of the final, fully processed BNP 
fragment varies between species. Human, pig, and dog BNP 
contain 32 amino acids,13,14 whereas rat and mouse BNP is a 
45 amino acid peptide.8,10,11,15–17 Compared to the sequence 
homology of atrial natriuretic peptide (ANP) and C-type 
natriuretic peptide (CNP) that are tightly conserved, the 
sequence homology of BNP differs across species both in 
size and amino acid sequence17,18 (Figure 2). This sequence 
variability may explain, in part, the variations of BNP 
biological activity in different species.
Although originally discovered in porcine brain, human 
BNP is expressed primarily in the cardiac atria and ventricles. 
The tissue concentration of BNP in the ventricle constitutes 
only about 1% of the atrium. However, the total BNP mRNA 
content is almost 3-fold higher in the ventricle.19 The majority 
of circulating BNP (60%) is released from ventricular 
tissues.19–22 This is in distinction from ANP, the great majority 
of which is synthesized and released by the cardiac atria.19 
These findings have prompted some investigators to suggest 
that ANP and BNP make up a dual cardiac peptide system 
with ANP the primary atrial peptide and BNP the primary 
ventricular peptide. In fact, some investigators have suggested 
Table 1 Updated clinical classification of pulmonary hypertension 
(Dana Point 2008)3
1. Pulmonary arterial hypertension (PAH)
  1.1. idiopathic PAH
  1.2. Heritable
    1.2.1. BMPr2
    1.2.2.     ALK1, endoglin (with or without hereditary hemorrhagic 
telangiectasia)
    1.2.3. Unknown
  1.3. Drug- and toxin-induced
  1.4.   Associated with
    1.4.1. Connective tissue diseases
    1.4.2. Hiv infection
    1.4.3. Portal hypertension
    1.4.4. Congenital heart diseases
    1.4.5. Schistosomiasis
    1.4.6. Chronic hemolytic anemia
  1.5 Persistent pulmonary hypertension of the newborn
1.   Pulmonary veno-Occlusive Disease (PvOD) and/or Pulmonary 
Capillary Hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
  2.1. Systolic dysfunction
  2.2. Diastolic dysfunction
  2.3.   valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
  3.1. Chronic obstructive pulmonary disease
  3.2. interstitial lung disease
  3.3.   Other pulmonary diseases with mixed restrictive and obstructive 
pattern
  3.4. Sleep-disordered breathing
  3.5.   Alveolar hypoventilation disorders
  3.6. Chronic exposure to high altitude
  3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTePH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
  5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
  5.2.   Systemic disorders: sarcoidosis, pulmonary Langerhans cell 
histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
  5.3.   Metabolic disorders: glycogen storage disease, Gaucher disease, 
thyroid disorders
  5.4.   Others: tumoral obstruction, fibrosing mediastinitis, chronic renal 
failure on dialysis
Abbreviations:   ALK1, activin receptor-like kinase type 1; BMPr2, bone morphoge-
netic protein receptor type.Drug Design, Development and Therapy 2009:3 272
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that BNP be renamed to ventricular natriuretic peptide to 
denote its greater importance in the cardiovascular system 
and to distinguish it from ANP.
Both atrial and ventricular BNP expression is induced 
within 1 hr of myocardial stretch from increases in venous 
volume or arterial pressure.23,24 Other stimuli that induce 
cardiac BNP secretion include hypoxia, ischemia, and states 
of nephrosis and cirrhosis that are associated with an increase 
in central blood volume.25–27 Several neuroendocrine mecha-
nisms also mediate cardiac BNP release.28,29 For example, 
α-adrenergic stimulation with phenylephrine results in 
increases in both BNP gene expression and BNP secretion, 
whereas myocardial stretch and endothelin-1 (ET-1) induce 
a marked increase in BNP gene expression alone.29,30
Atrial myocytes store pre-synthesized ANP and BNP 
in secretory granules and release them via a regulated 
pathway.31 Unlike ANP, however, most studies in normal 
subjects show no significant change in BNP levels in response 
to exercise.32–35 In patients with cardiac disease such as 
ischemia, hypertension or heart transplant recipients, exercise 
does induce a significant increase in BNP secretion.32–37 
These findings suggest that only under pathologic conditions 
is atrial BNP secreted during exercise-induced heart stress 
via a regulatory pathway in quantities sufficient to increase 
circulating levels. Ventricular myocytes also synthesize and 
secrete both peptides, but through a constitutive pathway.20 
Hence, it is possible that BNP is secreted by ventricular tissue 
during exercise. Most of the immediate release of BNP likely 
derives from atrial stores followed later by gene transcription 
and new protein synthesis from atrial and ventricular sources. 
BNP mRNA has a faster turnover rate than ANP due to 
the presence of mRNA-destabilizing AUUUA repeats in 
the 3’-untranslated region. This allows the synthesis and 
secretion of BNP in the ventricles to be closely controlled 
by mRNA levels according to changing amounts of load 
on the myocardium. The 5’-untranslated region of the gene 
possesses shear stress response elements and activation of 
MAPK and nuclear factor κB (NF-κB) is thought to be 
important in upregulating expression.38 The nuclear tran-
scription factor, GATA 4, plays a dominant role in regulating 
this process.39–41 The ability of BNP to be secreted from the 
heart in response to neurohormonal as well as hemodynamic 
stimuli and the rapid induction of BNP gene expression in 
response to ventricular strain make it a robust biomarker of 
cardiac stress and facilitates its use as a clinical tool.
BNP receptors
The diverse biological effects of BNP are mediated 
primarily by a membrane-bound particulate guanylyl cyclase 
receptor called natriuretic peptide receptor-A (NPR-A). 
NPR-A is widely expressed in the cardiovascular system 
including the cardiac atria and the ventricles as well as 
the aorta and peripheral vasculature, lungs, kidney, skin, 
platelets, and presynaptic sympathetic fibers.42–47 NPR-A 
has much higher affinity for ANP and BNP, than for CNP, 
but BNP is approximately 10-fold less potent than ANP in 
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generating particulate cGMP.48–50 Another membrane bound 
guanylyl-cyclase linked receptor, NPR-B, demonstrates 
high affinity for CNP and much lower affinity for ANP and 
BNP.49,51 Both NPR-A and NPR-B function as particulate 
guanylyl cyclases43,52 distinct from the cytoplastic soluble 
gaunylyl cyclase stimulated by nitric oxide (NO).53
Ligand binding to NPR-A or NPR-B activates the 
intracellular guanalyl cyclase domain of the receptor and 
catalyzes the synthesis of cGMP. There are three known 
proteins that bind cGMP with high affinity and act as 
downstream targets: cGMP-dependent protein kinase 
(PKG), cGMP binding phosphodiesterases (PDEs), and 
cyclic nucleotide-gated ion channels. PKG appears to be 
the principal intracellular mediator of cGMP signals.54–58 
Natriuretic peptide-induced elevation of intracellular cGMP 
causes a binding-dependent activation of PKG leading to 
the catalytic transfer of phosphate from ATP to a serine or 
threonine residue of target proteins. The phosphorylated 
proteins then determine the translation of the extracellular 
stimulus into a specific biological function.59
Cyclic nucleotides such as cGMP and cAMP are 
metabolized by a family of phosphodiesterases (PDE).60–63 
PDE-1, -2, -3, -10, and -11 degrade both cGMP and 
cAMP; PDE-4, -7, and -8 specifically hydrolyze cAMP; 
whereas PDE-5, -6, and -9 are highly selective for cGMP.64 
In vascular tissue, PDE-3 and -4 are responsible for most of 
the degradation of cAMP and PDE-5 is the major metabolic 
enzyme for cGMP. Despite the relative selectivity of PDE 
isoforms, both cAMP and cGMP can act as substrate for the 
other’s primary PDE and thereby impede its metabolism. 
There is clear evidence that this interaction between cyclic 
nucleotides and PDEs allows for crosstalk and integration 
between different pathways.60 PDE-5 is expressed in most 
vascular smooth muscle, is found in high concentration in the 
lung, and is increased in the lungs in experimental models of 
pulmonary hypertension.65,66 PDE-I in heart, lungs, brain, and 
smooth muscle is activated by binding of Ca2+-calmodulin 
to cause a decrease in cyclic nucleotide (cGMP or cAMP) 
concentration. Some PDEs are regulated allosterically by 
cGMP. For instance, in addition to its catalytic domain, PDE-5 
has additional binding sites for both cGMP and PKG that 
serve to stabilize the enzyme and enhance cGMP metabolism 
resulting in a feed-forward mechanism
BNP metabolism and clearance
Circulating natriuretic peptides are removed or metabolized 
via two major routes. One involves binding of the natriuretic 
peptide to natriuretic peptide receptor-C (NPR-C). NPR-C has 
an extracellular domain similar to that of NPR-A and NPR-B, 
but no intracellular guanylyl cyclase domain. Binding to 
the receptor is followed by endocytosis and lysosomal 
degradation,67 NPR-C has high affinity for all natriuretic 
peptides with a rank order of ANP  CNP  BNP in both 
humans and rats51,68 and has been proposed to function 
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primarily as a clearance receptor,46,69 although other biologic 
effects have been described.42
The second mode of metabolism is peptide cleavage 
and inactivation by neutral endopeptidase 24.11 (NEP).70 
This membrane bound zinc metalloproteinase is found on 
the luminal surface of endothelial cells and is particularly 
concentrated at the brush border membranes in the proximal 
tubule of the kidney. NEP inactivates and degrades both 
ANP and BNP,70,71 by opening their ring structures.72 The 
relative importance of the two clearance mechanisms is 
controversial, but it has been shown that in chronic heart 
failure, the clearance receptor NPR-C may play a lesser role 
than NEP in natriuretic peptide metabolism.73 Renal excretion 
of the peptides has also been described,74 but probably plays 
a minor role in regulating circulating concentrations of 
natriuretic peptides.
The circulating BNP level measured at any given time 
point is the result of the balance between BNP secretion and 
degradation. BNP has a plasma half-life of about 20 minutes, 
which is substantially longer than the 4 minute half-life 
reported for ANP.75 The longer half-life may be the result 
of more resistance to degradation by NEPs and less avid 
binding to NPR-C than ANP.76 Healthy individuals have 
plasma BNP concentrations around 1 fmol/ml (3.5 pg/ml) 
or approximately one-tenth that of ANP.77 However, plasma 
BNP levels in congestive heart failure patients can be 
200- to 300-fold higher. The enormous range of plasma BNP 
concentrations between healthy subjects and patients with 
heart failure and the rapid induction of BNP expression in 
response to acute overload or ischemia make it well suited 
to serve as an indicator of elevated myocardial loading and 
cardiac stress.78,79 The amino terminal fragment of proBNP 
(NT-proBNP) is less susceptible to degradation by NEP and 
is not cleared by NPR-C. As such, it may represent a more 
reliable indicator of cardiac BNP expression and secretion 
than circulating BNP levels. In fact, some studies suggest 
that plasma NT-proBNP levels may be a more sensitive and 
specific marker of cardiovascular disease than BNP.80,81 In 
patients, with left ventricular (LV) dysfunction NT-proBNP 
levels are up to 10 times higher than BNP.82 Unfortunately, 
NT-proBNP assays are not readily available in most clinical 
laboratories. A number of factors have been associated with 
higher BNP levels in addition to ventricular wall stress. 
Both BNP and NT-proBNP increase with age independent 
of the increased incidence of diastolic dysfunction.83 BNP 
and NT-proBNP levels are also higher in women than 
men at any age.84 The association between BNP and renal 
function is complex. Patients with chronic renal disease 
tend to have higher atrial pressure, systemic pressure, and 
ventricular mass, all of which would be expected to increase 
BNP synthesis and secretion. As mentioned previously, 
renal excretion of BNP has been described, but alterations 
in circulating levels in patients with renal disease are more 
likely related to decreased clearance by NPR-C and endopep-
tidases. NT-proBNP, in contrast, is predominantly excreted 
by the kidney, although plasma NT-proBNP, appears to 
maintain it’s clinical utility even in the presence of renal 
dysfunction.85,86
Use of BNP as a biomarker in PH
Pulmonary arterial pressure and rv strain
As in systemic hypertension, PAH is a hemodynamic 
diagnosis. The clinical manifestations of PAH and RV failure 
are non-specific, and are usually not evident on exam or 
general diagnostic tests such as chest roentgenogram and 
electrocardiogram until the disease is fairly advanced. 
Circulating levels of ANP and BNP correlate with mPAP,87 
but elevations in BNP levels are usually not seen until PAP is 
high enough to cause right ventricular strain. Therefore, BNP 
has limited diagnostic value as a screening tool for excluding 
PAH in populations at low risk for the disease. In select 
patient groups however, where the risk of PAH is substantially 
increased, such as those with connective tissue disease, portal 
hypertension, congenital systemic to pulmonary shunts, or 
a family history of IPAH, elevated BNP may help identify 
patients in whom further testing is warranted. For example, 
BNP may prove useful as a screening test for PAH in systemic 
sclerosis, where the prevalence of PH has been reported to 
be 12% to 35% and where PAH treatment has been shown 
to be beneficial.88–92 In 2003, Allanore et al obtained plasma 
NT-proBNP levels and echocardiographic estimates of peak 
PAP in 40 consecutive patients hospitalized for follow-up care 
of scleroderma (limited or diffuse disease).93 All patients were 
without symptoms of heart failure, had normal LV ejection 
fraction, and a creatinine clearance 58 mL/min. At baseline, 
10 patients (25%) were found to have PAH as defined by a 
peak right ventricular systolic pressure (RVSP)  40 mmHg. 
Thirteen patients had high NT-proBNP values (adjusted for 
age), including all 10 patients classified as PAH by TTE. 
There was a moderate correlation between peak RVSP and 
NT-proBNP level (r = 0.44, P = 0.006). A high NT-proBNP 
concentration (cutoff values supplied by the manufacturer 
and defined as above the 97th percentile) identified PH with 
a sensitivity of 90%, specificity of 90%, positive predic-
tive value of 69%, and negative predictive value of 96%. 
Although the sensitivity and specificity of transthoracic echo Drug Design, Development and Therapy 2009:3 275
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for detecting PH is only about 90% and 75% respectively, 
subsequent studies using right heart catheterization to define 
PAH have obtained similar results.94 Mukerjee et al identi-
fied found PAH by RHC in 23 of 49 patients with SSc.95 
The mean value of NT-proBNP in patients with PAH was 
3365 ± 1095) pg/mL compared to 347 ± 174 pg/mL for 
patients without PAH. There was a statistically significant 
correlation (P  0.05) between NT-proBNP values and 
(i) mPAP (r = 0.53), (ii) right ventricular end diastolic pressure 
(r = 0.59) and (iii) PVR (r = 0.49). Receiver operator charac-
teristic curve analysis showed that a cut-off value of 395.34 
pg/mL had a sensitivity of 0.69 and specificity of 1.0. The 
same group performed a larger study to assess prospectively 
the specificity of 395 pg/mL in a larger population and to 
evaluate the prognostic value of NT-proBNP in a homog-
enous group of patients with scleroderma associated PAH 
(SSc-PAH).94 The study population included 68 individuals 
with PAH mPAP  25 mmHg and PCWP  15 mmHg 
and 41 individuals without PAH. The patients without 
PAH had a lower mean NT-proBNP level than those with 
SSc-PAH baseline NT-proBNP levels were correlated 
positively with mPAP (r = 0.62; P  0.0001), PVR (r = 0.81; 
P  0.0001), and inversely with 6 minute walking distance 
(6MWD) (r = –0.46; P  0.0001). At an NT-proBNP level 
of 395 pg/mL, the sensitivity and specificity for predicting 
the presence of SSc-PAH were 56% and 95% respectively. 
Thus NT-proBNP estimation in systemic sclerosis-related 
PAH is a potentially useful diagnostic tool. Similarly, subjects 
with lung fibrosis and elevated BNP levels (n = 20) had 
significantly higher PAP than those with normal BNP levels 
(mean pulmonary arterial pressure (40.85 ± 3.2 mmHg vs 
23.42 ± 1.44 mmHg, (P  0.001).96
Although TTE is the most commonly used test to diagnose 
or exclude PH, its specificity is low in early disease.95 For 
example, a RVSP  40 mmHg commonly used cut off level 
to separate normal from elevated PAP has been found in 6% 
of individuals older than 50 years of age and in 5% of patients 
with a body mass index 30 kg/m2 in the absence of pul-
monary hypertension.97 In patients such as these, an elevated 
plasma BNP level may improve the diagnostic accuracy of 
TTE in screening for PAH. Two recent studies have demon-
strated the potential utility of exercise echocardiography in 
identifying individuals at risk for future development of PH 
in at risk populations.98,99 It is interesting to speculate whether 
increased levels of BNP during exercise would improve the 
predictive accuracy of this emerging technology.
In addition to PAP, plasma BNP levels are a reliable 
marker of right heart strain, which is a significant predictor of 
morbidity and mortality in PAH and other forms of pulmonary 
disease causing pulmonary hypertension.100,101 Elevated BNP 
is not specific for right or left sided heart disease, but in the 
absence of left sided heart disease, may prove to be useful 
adjunct to echocardiography in evaluating right heart stress. 
In patients with right ventricular pressure overload associated 
with idiopathic PAH or CTEPH, BNP levels were significantly 
higher than in controls (294 ± 72 pg/mL versus 48 ± 14 pg/mL 
(P  0.05).100 In this study, BNP levels correlated with, right 
ventricular end diastolic pressure (r = 0.76) as well as mPAP 
(r = 0.73) and total pulmonary resistance (TPR) (r = 0.79). 
Long-term treatment with either prostacyclin or prostaglandin 
E reduced TPR (from 23 to 15 Wood units) and cut plasma 
BNP by more than half (315 ± 120 to 144 ± 54 pg/mL). BNP 
levels have also been shown to be higher in acute pulmonary 
embolism and to fall following thromboendarterectomy in 
patients with CTEPH.100,102 Conversely, right ventricular 
dilation is exceedingly uncommon in acute PE when plasma 
troponin and BNP levels are normal.103 Souza et al demon-
strated a close correlation between PVR and NT-proBNP 
(r = 0.80, P  0.001) in 42 patients with IPAH.104 BNP 
levels also correlate with functional capacity in PAH. In one 
study, BNP levels were inversely correlated with 6MWD 
(r = –0.70; P  0.001) and peak VO2 (r = –0.61; P  0.01), 
and positive correlation with WHO functional class (r = 0.79; 
P  0.001) in 42 patients with IPAH.96
Survival and response to therapy
Plasma BNP levels have been shown to have significant 
prognostic capabilities in patients with PAH.105 One study 
measured plasma BNP levels in 60 patients with IPAH 
at initial right heart catheterization and compared the 
prognostic significance of baseline and follow-up BNP 
levels with clinical, echocardiographic, and hemodynamic 
variables. Patients with renal insufficiency were excluded. 
Measurements were repeated in 53 patients at 3 months. 
Plasma BNP was increased at baseline and correlated 
positively with New York Heart Association (NYHA) func-
tional class (Figure 3), mPAP, mean RAP, and TPR, and 
correlated negatively with cardiac output. Mean follow-up 
averaged 24 months, during which time 18 patients died of 
cardiopulmonary causes. Among the noninvasive baseline 
parameters studied, only plasma BNP was an independent 
predictor of mortality by multivariate analysis. Kaplan-Meier 
analysis demonstrated that follow-up BNP provided a more 
distinct separation of survival curves than did baseline BNP 
measurement (Figure 3). Survival was markedly improved in 
those patients with a follow-up BNP level below 180 pg/mL. Drug Design, Development and Therapy 2009:3 276
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In fact, receiver operating characteristic analysis suggested 
that baseline BNP was at least equal to mPAP and superior to 
CO in predicting mortality. These findings were substantiated 
by Fijalkowska et al who demonstrated in their 36 IPAH 
patients that a serum NT-proBNP level of 1400 pg/mL 
identified patient with a poor long term prognosis estimated 
by Kaplan-Meier cumulative survival curves.106
Plasma NT-proBNP levels have also been shown 
to predict survival in patients with PH (Figure 4). The 
use of NT-proBNP to predict survival was assessed 
in 68 patients with SSc-PAH94 over a mean duration of 
10 months (range 1 to 18 months). The mean NT-proBNP 
level in patients without PAH was significantly lower than 
in those with SSc-PAH (P = 0.0002). For every order of 
magnitude increase in NT-proBNP level in patients with 
PAH, the risk of death increased 4-fold (P = 0.002 for 
baseline level and P = 0.006 for follow-up level). Base-
line NT-proBNP levels correlated directly with mPAP 
(r = 0.62; P  0.0001), PVR (r = 0.81; P  0.0001), and 
inversely with 6MWD (r = –0.46; P  0.0001). Plasma 
NT-proBNP levels also identified differences in functional 
class among patients with SSc-PAH. The 13 patients (19%) 
in WHO functional class II had mean N-TproBNP levels of 
325 ± 388 pg/mL, whereas the 53 patients (78%) in WHO 
classes III and IV had mean NT-proBNP levels that were 
5-fold higher (1677 ± 2835 pg/mL, P = 0.02).
The correlation of circulating BNP levels with pulmonary 
hemodynamics, right heart strain and survival has generated 
interest in using it as a noninvasive assessment of response 
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to therapy. In an early study of nine patients with IPAH who 
underwent prostaglandin therapy,87 plasma BNP levels fell 
in conjunction with TPR after a mean follow-up of 35 days 
(TPR 23 ± 4 to 15 ± 3 Wood units, P  0.05; plasma 
BNP 315 ± 120 to 144 ± 54 pg/mL P  0.05). In a larger 
follow-up study by Nagaya and colleagues, BNP measure-
ments were repeated after 3 months of vasodilator therapy 
in 49 patients with idiopathic PAH.105 Changes in plasma 
BNP were associated with changes in RV end-diastolic 
pressure and TPR but not mPAP or right ventricular dimen-
sion. During prostacyclin therapy, plasma BNP significantly 
decreased in survivors but increased in non-survivors. Park 
and colleagues studied 20 patients with PAH on epoprostenol 
and similarly found that BNP may help predict those who 
are refractory to treatment.107 Leuchte et al found that BNP 
levels parallel changes in pulmonary hemodynamics and 
functional parameters, including 6MWD, in 30 patients with 
PAH.108 Progression of the disease was accompanied by an 
increase in BNP levels, whereas improvement of pulmonary 
hemodynamics and functional status was accompanied by a 
significant decline in plasma BNP concentrations. Findings 
from studies such as these suggest that serial plasma BNP 
could be useful in monitoring the efficacy of therapy in PAH 
patients and this approach is reflected in recent guidelines 
from the American College of Cardiology that suggest the 
use of plasma BNP levels in assessing the risk of deteriora-
tion in patients with PAH.109 Although one-time measures 
of circulating BNP may be difficult to interpret, serial BNP 
testing may provide a non-invasive measure to help identify 
patients who are failing their current therapeutic regime and 
predict RV decompensation before it becomes clinically 
apparent. This is supported by the finding that higher BNP 
levels at presentation with pulmonary embolism is associ-
ated with increased mortality in two recent studies with 
large cohorts of patients.110,111 These findings suggest that in 
pulmonary embolism at least, BNP can help identify patients 
with increased right ventricular strain at higher risk for acute 
decompensation.
Effect of BNP on right ventricle  
and pulmonary circulation
In addition to being a biomarker of elevated PAP and right 
heart failure, BNP has many biologic properties that could 
be beneficial in combating progressive pulmonary vascular 
disease. These properties have piqued the interest of investi-
gators and clinicians in BNP as a potential therapeutic target 
in the management of PAH. Before discussing therapeutic 
approaches, a review of the current understanding of 
BNP effects on the heart and pulmonary circulation is 
presented.
effect on PA pressure
BNP relaxes preconstricted isolated pulmonary arteries and 
blunts hypoxic pressor responses in isolated perfused rat 
lungs with a potency similar to that of ANP (Figure 5).112 
Although circulating BNP levels are an order of magni-
tude lower than ANP, the percent increases in plasma BNP 
levels and right heart BNP expression during exposure to 
chronic hypoxia are similar for both peptides.112 These data 
suggest that BNP, in concert with ANP, may play a role in 
modulating pulmonary hypertensive responses and protecting 
the right heart from the development of hypoxic pulmonary 
hypertension. In one study, BNP was more effective than 
ANP at blunting pulmonary hypertension in rats exposed 
to 3 weeks of hypoxia.113 Furthermore, mice deficient in 
NPR-A, the receptor that mediates the pulmonary vasodilator 
effects of both ANP and BNP develop greater pulmonary 
hypertension and right ventricular hypertrophy than wild type 
mice after exposure to chronic hypoxia.114,115 These studies 
suggest that ANP and BNP signaling through NPR-A play 
important roles in regulating pulmonary vascular tone and 
in the pathogenesis of hypoxia-induced pulmonary hyper-
tension. Interestingly, chronic hypoxia causes a significant 
downregulation of NPR-C expression in pulmonary vascular 
smooth muscle in vitro and a marked decrease in pulmonary 
clearance of ANP in intact rats.116,117 This may represent a 
compensatory response of the lungs to increase the circulating 
levels of natriuretic peptides in the pulmonary vasculature and 
attenuate the effect of hypoxic pulmonary hypertension.
effect on pulmonary vascular smooth 
muscle proliferation
In addition to its vasorelaxant effects, BNP has antiprolifera-
tive effects on vascular smooth muscle cells in culture and thus 
may play a role in inhibiting pulmonary vascular remodeling.118 
ANP has been shown to inhibit the effect of several growth 
factors on the proliferation of smooth muscle cells isolated 
from the systemic vascular bed, however few studies have 
examined the effect of the natriuretic peptides on inhibition of 
pulmonary vascular smooth muscle cell proliferation. Arjona 
et al found that BNP inhibited proliferation of serum stimu-
lated pulmonary vascular smooth muscle cells and increased 
generation of intracellular cGMP.119 In preliminary studies 
we have shown that ANP inhibits PDGF-induced prolifera-
tion of pulmonary vascular smooth muscle cells as well and 
that this effect is absent in cells isolated from NPR-A knock Drug Design, Development and Therapy 2009:3 278
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out mice.120 Together, these studies suggest that ANP and 
BNP are capable of modulating proliferation of pulmonary 
vascular smooth muscle via signaling through NPR-A and 
elevation of cGMP. These findings are consistent with reports 
showing that pulmonary vascular remodeling is reduced in 
rats given ANP or BNP infusion during exposure to chronic 
hypoxia113, 121 and that mice with gene-targeted disruption of 
ANP or NPR-A have greater pulmonary vascular remodel-
ing under normoxic conditions and after hypoxic exposure 
than wild-type littermates.114,115,122
effect on right ventricular hypertrophy
The natriuretic peptide system also plays an important 
role in inhibiting maladaptive hypertrophic responses in 
cardiac myocytes. Numerous studies have demonstrated that 
cardiac hypertrophy in response to a sustained increased in 
ventricular afterload is associated with a marked increase in 
ventricular ANP and BNP mRNA expression. This response 
is seen in both the right and left ventricle in response to a 
variety of hypertrophic stimuli such as chronic hypoxia, 
monocrotaline-induced pulmonary hypertension or aortic 
banding.122–124 Initially, this finding was attributed to the 
activation of a program of fetal genes during hypertrophy 
of cardiac myocytes.125 As a result, increased ventricular 
expression of ANP and BNP was considered a marker of 
maladaptive cardiac hypertrophy. However, other studies 
have shown that the degree of hypertrophy is inversely 
related to ANP expression and genetic disruption of 
ANP, BNP or NPR-A results in increased biventricular 
cardiac mass under baseline conditions and exagger-
ated hypertrophic responses to aortic banding or chronic 
hypoxia.114,122,124,125 In addition, hearts of mice with disrupted 
ANP/BNP-NPR-A signaling have increased deposition 
of collagen and decreased contractility suggesting that 
the natriuretic peptides play important roles in mediating 
maladaptive cardiac hypertrophic effects.126
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Although BNP and ANP appear to signal through the same 
receptor, mice with targeted deletion of BNP exhibit a different 
phenotype than ANP-deficient mice. Mice without ANP are 
hypertensive at sexual maturity and this has not been demon-
strated in mice without BNP. Thus, gene deletion experiments 
suggest that ANP and BNP have distinct physiologic effects 
and that ANP and BNP may play complementary roles in the 
regulation of cardiovascular homeostasis through NPR-A.
BNP has been shown to inhibit proliferation of cardiac 
fibroblasts in culture.127 This observation was validated 
in vivo when ventricular pressure overload caused by 
abdominal aortic banding induced an increase of multi-focal 
fibrotic lesions in the ventricles in mice lacking BNP, but not 
in wild-type mice, despite a similar increase in ventricular 
mass between the two genotypes.128 In this study, ventricular 
fibrosis was associated with a marked increase in expression 
of angiotensin converting enzyme, transforming growth 
factor-β3 (TGFβ3), and pro-α1(I) collagen, factors that are 
implicated in the generation and progression of ventricular 
fibrosis.128 Finally, BNP has been shown to almost completely 
abolish TGFβ-induced increases in collagen secretion from 
cardiac fibroblasts.129 Taken together, these results indicate 
that BNP exerts antifibrotic as well as antihypertrophic 
effects on the heart and plays an important role in mitigating 
maladaptive cardiac hypertrophic responses.
The mechanism involved in BNP regulation of fibroblasts 
is unclear. Kapoun et al found that BNP treatment inhibited 
TGFβ-induced expression of genes related to fibrosis, 
(collagen 1, fibronectin, CTGF, PAI-1, and TIMP3, 
myofibroblast conversion (alpha-smooth muscle actin 2 and 
nonmuscle myosin heavy chain), proliferation (PDGFA, 
IGF1, FGF18, and IGFBP10), and inflammation (COX2, 
IL6, TNFα-induced protein 6, and TNF superfamily).129 
Other studies have found that ANP and BNP modulate the 
matrix metalloproteinases, enzymes that play important 
roles in regulating the production of extracellular matrix 
proteins.129–131
It can be difficult to separate the antihypertrophic effect 
of BNP from its vasorelaxant properties. Studies of BNP and 
NPR-A knockout mice typically show increases in systemic 
arterial and pulmonary arterial pressure as well as cardiac 
hypertrophy, although the hypertrophic effect of disrupted 
NPR-A signaling has been more pronounced than its effect 
on arterial pressure. To differentiate the cardiac from the vas-
cular effects of ANP and BNP, Holtwick et al developed mice 
with conditional, selective deletion of NPR-A in cardiomyo-
cytes mice.120 The endocrine, blood pressure- and volume-
regulating effects of ANP were found to be preserved in these 
mice but significant cardiac hypertrophy was still observed. 
These findings suggest that NPR-A signaling indeed func-
tions as counter-regulatory hypertrophic circuit in the 
heart under both basal and pressure-overload conditions.132 
Interestingly, in humans, certain ANP- and BNP-receptor 
polymorphisms have been associated with left ventricular 
mass in essential hypertension.133 In addition, a deletion in 
the 5’-flanking region of the gene encoding NPRA has been 
associated with hypertension and hypertrophy.134
effect on pulmonary endothelial 
proliferation and apoptosis
Preservation of endothelial function is critical in combating 
pulmonary vascular disease.
Recent studies demonstrate that the NO/sGC/cGMP 
pathway complements natriuretic peptide/pGC/cGMP such 
that suppression of one pathway decreases the sensitivity 
of the other.135,136 The reciprocal regulation of natriuretic 
peptides and nitric oxide suggest that natriuretic peptides 
could play a key role in treating diseases like PAH that are 
associated with deficiencies in NO production. Interactions 
between natriuretic peptides and ET-1 may also be 
important. BNP can directly inhibit ET-1 synthesis as well as 
functionally antagonize ET-1-induced vasoconstriction and 
cardiomyocyte hypertrophy.137 These molecular interactions 
may play a significant role in the cardioprotective function 
of natriuretic peptides in PAH. Furthermore, classic 
heterologous desensitization of NPR-A, ie, the ability of 
other cGMP-elevating enzymes to desensitize NPR-A, does 
not seem to occur.138 This supports important reciprocal 
regulation of vascular tone by natriuretic peptides and 
NO, which activate the particulate and soluble isoforms of 
guanylate cyclase, respectively.135,136
Impaired apopotosis of pulmonary vascular endothelial 
cells may play an important role in the pathogenesis of 
pulmonary arterial hypertension. Tuder et al have proposed 
that impaired apoptotic responses in pulmonary vascular 
endothelial cells favors the emergence of apoptosis- resistant 
endothelial cells leading to uncontrolled proliferation in 
PAH.4,139,140 ANP, BNP and CNP are all capable of inducing 
apoptosis in cultured rat endothelial cells,141 but the extent 
to which they modify apoptosis under such circumstances 
has not been fully defined. During ischemia/reperfusion 
in rodents and humans, 5% to 30% of cardiac myocytes 
in the area at risk undergo apoptosis within 16 hours.142 
Kato et al reported that ANP significantly inhibits apopto-
sis in rat cardiac myocytes and that this effect is mediated 
by the increase in cGMP followed by activation of the Drug Design, Development and Therapy 2009:3 280
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Akt/PI3K pathway.143 Conversely, ANP has been shown to 
induce cell cycle entry in terminally differentiated chick 
cardiac myocytes, and to induce apoptosis in a model of 
neonatal rat cardiac myocytes.144 Therefore, it appears that 
natriuretic peptides can modulate apoptosis in cardiac myo-
cytes as well as endothelial cells, but to what extent this 
occurs in pulmonary vascular endothelial cells and/or the 
right ventricle in PAH is uncertain.
Effect of BNP on inflammation 
and oxidative stress
The pathological lesions in IPAH include areas of marked 
intima remodeling and near complete obliteration by 
fibrous tissue. Intravascular and perivascular inflammatory 
infiltrates have also been described, suggesting that vascular 
inflammation may contribute to the pulmonary vascular 
remodeling seen in some forms of PAH. BNP has the ability 
to modulate the production of inflammatory mediators in 
activated macrophages such as leukotriene B4, prostaglandin 
E2 and the cytokines (TNFα, IL-12 and IL-10).145 Interest-
ingly, NPR-A knockout mice exhibit decreased neutrophil 
infiltration to cardiac tissue after ischemic injury compared 
with wild-type mice by decreasing activation of the transcrip-
tion factor NF-κβ.146
Oxidative stress also contributes to the pathophysiology 
of inflammation in the cardiovascular system.147 Reactive 
oxygen species are produced in the lung tissue of patients 
with severe pulmonary hypertension as a consequence of 
tissue hypoxia148,149 or ischemia150 or through the activa-
tion of inflammatory cascades and increased production of 
inflammatory cytokines.151,152 BNP reduces the production of 
free radicals, such as reactive oxygen- and nitrogen species 
from activated macrophages thereby reducing oxidative 
stress during inflammation.145 This may represent another 
potential mechanism by which BNP could protect against 
the progression of vascular disease and endothelial dysfunc-
tion in PAH.
Potential role for BNP  
in treatment of PH
As described above, BNP influences a variety of biologic 
processes in a manner that has the potential to benefit patients 
with PAH. Unfortunately, the peptide structure of BNP results 
in rapid degradation in the gastrointestinal tract following 
ingestion, making oral delivery challenging. Intravenous 
infusion of BNP is feasible using recombinant human BNP 
developed for the treatment of acute decompensated heart 
failure (nesiritide; Natrecor®). Inconvenience, expense and 
potential safety concerns of continuous intravenous infusion 
are barriers to conducting even small proof of concept 
clinical trials. Although it should be acknowledged that 
long-term intravenous infusion has been used successfully 
for prostacyclin therapy in PAH. Most of the information 
available on the use of BNP to treat cardiovascular disease 
derives from clinical trials in congestive heart failure and 
acute renal failure and a handful of reports of its acute 
effects on the pulmonary circulation.153,154 As a result, there 
are limited data on the efficacy or safety of BNP for the 
treatment of PAH.
BNP has biological effects that are similar to those of ANP, 
but its circulating levels are much lower and in the absence of 
any physiological derangements, small increases in plasma 
BNP levels are unlikely to have significant cardiovascular 
effects. This is supported by most human studies in which 
physiological doses of BNP given to healthy volunteers have 
little effect on blood pressure, heart rate, angiotensin II, or 
aldosterone synthesis.155–160 However, at supra-physiological 
doses, BNP has been shown to have hypotensive and diuretic 
properties. For example, infusion of pharmacological doses 
of BNP into normal subjects leads to a rapid and sustained 
reduction in mean arterial blood pressure.161 The fall in 
blood pressure is not solely a consequence of vasodilation, 
but also related to reduced stroke volume and intravascular 
volume. Pharmacologic doses of BNP have also been shown 
to have an acute pulmonary vasodilator effect in humans. 
Intravenous infusion of human BNP (10 pmol kg−1 min−1) 
blunts the acute pulmonary vasoconstrictor response to 
hypoxia162 and reduces PA pressure in patients with cor 
pulmonale.163 These preliminary studies demonstrate that 
BNP is capable of reducing elevated PAP in some forms of 
pulmonary vascular disease.
Clinical experience with BNP infusion in patients 
with PAH is extremely limited. Michaels et al reported the 
hemodynamic effects of intravenous nesiritide infusion in 
five patients with precapillary PH.164 At 15 and 30 minutes 
following infusion, there was a decrease in systemic arterial 
pressure but no change in right-sided heart pressures or CO. 
Klinger et al found that a 3-hour BNP infusion alone, 
although well tolerated in adult patients with PAH, had no 
effect on mPAP or PVR.165 However, the combination of 
sildenafil followed by BNP infusion caused a statistically 
significant reduction in both parameters that persisted for 
up to 6 h after stopping the BNP infusion (Figure 6). The 
reduction in mPAP with sildenafil plus BNP was at least as 
great as that seen with any of the other pulmonary vasodila-
tors used in this trial and greater than that observed 1 hour Drug Design, Development and Therapy 2009:3 281
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after sildenafil alone. Thus, BNP may be able to potentiate 
the acute vasodilator effects PDE-5 inhibitors.
In addition to its diuretic and acute pulmonary vasodilator 
effect, the natriuretic peptides generally oppose the actions of 
angiotensin II, ET-1, and the sympathetic nervous system137 
and thereby have the potential to improve right ventricular 
function in patients with PAH. Nesiritide administration leads 
to a rapid vasodilatory effect and decrease in both right and 
left ventricular filling pressures and pulmonary capillary 
wedge pressures166 and has been shown to have therapeutic 
potential in slowing progression of right ventricular 
dysfunction.167
There is increasing recognition that left heart failure 
may have a relative natriuretic deficient or resistant state. 
Elevated plasma levels of ANP and BNP are found in patients 
with congestive heart failure and the magnitude of increase 
coincides with the severity of heart failure.168–170 Studies 
of early LV dysfunction have demonstrated that natriuretic 
peptides play an important role in maintaining cardio-renal 
homeostasis through systemic actions that antagonize volume 
overload.171 Gene deletion studies confirm that NPR-A 
signaling protects against heart failure induced by volume 
overload in mice.172 However, in severe symptomatic HF, 
there is sodium and water retention associated with increased 
systemic vascular resistance and high cardiac filling pressures 
despite extremely high plasma concentration of immuno-
reactive ANP and BNP. The discrepancy in plasma levels 
of natriuretic peptides and their apparent lack of effect on 
cardiorenal physiology is not clearly understood, but may 
be due to impaired NP synthesis and release, a down regu-
lation of NPRs at the tissue level, or increased metabolism 
of cGMP. Animal studies have shown an up-regulation of 
PDE expression in left ventricular failure, causing impaired 
cGMP activity despite high stimulation of the guanylyl 
cyclase-linked NPRs.173 Supaporn et al have reported similar 
increases in PDE-1 and PDE-5 in severe congestive HF in 
humans.174 Abnormal processing of proBNP into less active 
forms has also been described in congestive heart failure.175 
Resistance to natriuretic peptides may explain the variable 
response rate and the need for high doses that character-
ized the early clinical trials of BNP in congestive heart 
failure.176–179 Recent analyses of clinical trial data of nesiritide 
have raised concerns about adverse renal effects.180,181 The 
use of nesiritide at the dosages described in the package 
insert (0.01 to 0.03 µg kg–1 min–1) was noted to be associ-
ated with a dose-dependent increase in serum creatinine. 
Furthermore, this was exacerbated by systemic hypotension 
a known adverse effect of nesiritide. This clinical experience 
needs to be considered in future trials of BNP in pulmonary 
hypertension.
As discussed previously, BNP has significant antihy-
pertrophic and anti-fibrotic effects on myocardiocytes. 
It is conceivable that prolonged administration of BNP may 
mitigate maladaptive hypertrophic responses in the right 
ventricle. In a small randomized trial of PAH, Wilkins et al182 
found that patients treated with sildenafil had a significant 
reduction in right ventricular mass as measured by MRI that 
was not found in those who received the endothelin receptor 
antagonist bosentan, despite a similar degree of improvement 
in 6MWD. Further augmentation of cGMP with the combi-
nation of BNP infusion and PDE inhibition may inhibit RV 
hypertrophy and fibrosis and help to preserve RV function. 
This idea is supported by the report Khush et al of 10 patients 
with precapillary PH that had acute elevations in pulmonary 
NO and cGMP levels post nesiritide infusion.183
To advance the use of BNP as a therapy for PAH, more 
practical methods will likely be needed to increase plasma 
BNP levels. Subcutaneous administration of BNP has been 
used successfully in animal and in clinical studies to increase 
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plasma BNP and its second messenger 3’,5’-cyclic guanosine 
monophosphate (cGMP) with subsequent natriuresis and 
reduction in cardiac filling pressures.184–189 In one canine 
study,188 tolerance was not observed following chronic 
administration of BNP. Development of orally available 
peptides has long been a challenge, given various barriers 
to protein absorption and penetration.190 Recently, Cataliotti 
et al191 reported the application of proprietary technology that 
enabled oral delivery of BNP by covalently attaching short, 
amphiphilic oligomers to peptides. In normal conscious 
dogs, this novel oral conjugated human BNP activated 
cGMP and exerted hypotensive effects.191 Recently, Cataliotti 
et al192 further demonstrated in a canine model of acute 
hypertension that a more advanced oral conjugated human 
BNP significantly increased cGMP and lowered MAP. The 
availability of an orally active NP such as BNP could lead 
to a much wider application of these peptides. An alternative 
approach would be to impede degradation of endogenous 
BNP through NEP inhibition. Neutral endopeptidase is a 
major enzymatic pathway for the degradation of BNP and 
also plays a role in kinin and adrenomedulin breakdown.193 
Inhibition of NEP increases plasma levels of BNP193 and has 
been shown to inhibit hypoxic pulmonary hypertension in 
rats,194 although the mechanism by which this was achieved 
is not known.
In summary, although few clinical data currently exist, 
there is evidence to suggest that enhancement of BNP 
activity, especially in combination with other agents that 
increase cGMP signaling has the potential to aid in the 
treatment of PAH.195,196 Perhaps most intriguing of the 
pleiotropic effects of BNP is its antiproliferative/antifibrotic 
properties and the potential for reversing the maladaptive 
remodeling associated with PAH.
Summary
BNP is an integral part of the natriuretic peptide system 
that functions as a hormonal regulator of cardiovascular 
homeostasis. Like ANP, it is capable of relaxing pulmonary 
vascular smooth muscle, especially under condition in 
which vascular tone is increased. It also shares with ANP 
diuretic, antimitogenic, antifibrotic and antihypertrophic 
effects that have the potential to limit pulmonary vascular 
remodeling and maladaptive hypertrophic responses in the 
right ventricle. Right ventricular expression and circulating 
levels of BNP rise markedly in patients with pulmonary 
hypertension and correlate with severity of disease and 
mortality. Changes in BNP expression are more prominent in 
the ventricle than ANP expression, particularly during times 
of increased ventricular overload. This ventricular response, 
along with its slower clearance from the circulation appears 
to be responsible for BNP acting as a better biomarker of 
ventricular function than ANP. Monitoring of BNP and 
its precursor NT-ProBNP provides important objective 
information regarding the ability of the right ventricular to 
compensate for increased after load as pulmonary vascular 
disease progresses. The prognostic significance of plasma 
BNP on survival in pulmonary hypertension is independent 
of hemodynamic variables and provides the practitioner 
another tool with which to assess prognosis and response 
to therapy. Findings from in vitro and intact animal studies 
suggest that administration of exogenous BNP is capable 
of blunting pulmonary vasoconstriction and inhibiting the 
development of pulmonary hypertension, right ventricular 
hypertrophy and pulmonary vascular remodeling. However, 
lack of a convenient method for achieving sustained increases 
in circulating BNP levels has impeded the development 
of BNP as a therapy for treating pulmonary hypertension. 
Further study is needed to determine if BNP can potentiate 
the pulmonary vasodilator effects of phosphodiesterase 
inhibitors and blunt or reverse maladaptive hypertrophic 
responses in the right ventricular. New technologies that 
allow transdermal or oral administration of the natriuretic 
peptides have the potential to greatly accelerate research into 
therapeutic use of BNP for cor pulmonale and pulmonary 
vascular diseases.
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